HK Stock Market Move | LAENKA-B(02105) rose more than 4% LAE102 completes Phase I single dose escalation study and will initiate multiple dose escalation study in the first quarter.

LAEKNA-B (02105) rose more than 4%, as of the time of writing, it has risen by 4.69% to 10.26 Hong Kong dollars, with a trading volume of 35.39 million Hong Kong dollars. In terms of news, Laike Pharmaceuticals recently announced that its independently developed LAE102 (ActRIIA monoclonal antibody) has made significant progress in the Phase I clinical trial for overweight/obesity in China: the single dose escalation study (SAD study) has been successfully completed. The SAD study recruited a total of 64 healthy volunteers, with an average BMI of 23.22.2 kg/m2, including 5 intravenous dosing cohorts and 3 subcutaneous dosing cohorts. The results of the SAD study lay a solid foundation for the upcoming Phase I multiple ascending dose study (MAD study) in China, as well as the Phase I clinical study being conducted in collaboration with Eli Lilly in the United States. The company stated that the positive results of the SAD study support further research on the use of LAE102 for the treatment of obesity. The company plans to initiate the Phase I MAD study in the first quarter of 2025, and collaborate with Eli Lilly to initiate a Phase I study in the United States as soon as possible. The Phase I MAD study is a randomized, double-blind, placebo-controlled study aimed at evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneous LAE102 in 60 overweight/obese subjects.